Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, and Diabetes Management and Research.
Pharmacological therapies for type 2 diabetes: future approaches.
Metformin: Antidiabetic actions from cells to tissues.
Metformin: Therapeutic profile in the treatment of type 2 diabetes.
Recent advances in peptide-based therapies for obesity and type 2 diabetes.
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes.
Diabetes and gout: another role for SGLT2 inhibitors?
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
An update on peptide-based therapies for type 2 diabetes and obesity.
Continuous Glucose Monitoring Impact and Implications of Real-World Evidence: Past, Present, and Future.
Synthalin: a lost lesson for glucagon suppression in diabetes therapeutics.
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.
Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.
Odd chain fatty acid metabolism in mice after a high fat diet.
From insulin injections to islet transplantation: An overview of the journey.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Type 2 diabetes mellitus in older adults: clinical considerations and management.
Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen.
Flash Continuous Glucose Monitoring: A Summary Review of Recent Real-World Evidence.
Tirzepatide: a new low for bodyweight and blood glucose.
The potential role of multifunctional human amniotic epithelial cells in pancreatic islet transplantation.
Recent advances in peptide-based therapy for Type 2 diabetes and obesity.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
GIP analogues and the treatment of obesity-diabetes.
Reports of Lactic Acidosis Attributed to Metformin, 2015-2018.
Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
Metformin in women with type 2 diabetes in pregnancy.
Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2020;43:244-246.
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.